SAN DIEGO and SUZHOU, China, Dec 14 (Bernama-GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced preclinical data demonstrating the compelling differentiation of ADG153, an anti-CD47 monoclonal antibody (mAb), and ADG152, a CD20xCD3 bispecific T-cell engager (TCE). The data were presented in two poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition taking place December 11-14, 2021, which are available in the Publications section of the company’s website at www.adagene.com.
http://mrem.bernama.com/viewsm.php?idm=41919
- Algerian Parliamentary Speaker Condemns “Silence, Complicity” Over Israeli Attacks On Gaza, Lebanon
- Egyptian PM Inaugurated Int’l Manufacturing Exhibition
- World Investment Conference Kicked Off In Riyadh
- Two More Palestinian Boys Shot Dead By Sadistic Zionist Army In N. West Bank
- Update: 16 Still Missing After Safari Boat Sank Off SE Egypt
- Russia Could Deploy Missiles In Asia If U.S. Missiles Appear There: Deputy FM
- Indonesia To Run Regional Elections Tomorrow
- Lee Hsien Loong Supports Lawrence Wong To Lead Singapore’s Ruling Party
- 18 Killed, Over 30 Injured In Armed Clashes In NW Pakistan
- Iraq Warns Of Possible Israeli Attacks In Letters To UN